Joao Victor Alessi

24PUBLICATIONS
276CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPeripheral nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Sep 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Alessio Cortellini, Valentina Santo, Leonardo Brunetti

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

|Apr 09, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.

Seshiru Nakazawa, Federica Pecci, Igor Odintsov

|Feb 04, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio

|Jan 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.

Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte

Pageof 4

Frequent Collaborators

23 joint publications

Biagio Ricciuti

19 joint publications

Mark Magdi Awad

11 joint publications

Alessandro Di Federico

8 joint publications

Giuseppe Lamberti